Buprenorphine and methoclocinnamox: Agonist and antagonist effects on respiratory function in rhesus monkeys

European Journal of Pharmacology

Volumn 391, Issue 3, 2000, Pages 289-297

  Kishioka, Shiroh ^a   Paronis, Carol A ^a   Lewis, John W ^b   Woods, James H ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

(Rhesus monkey); Buprenorphine; Methoclocinnamox; Opioid receptor agonist; Opioid receptor antagonist; Respiration

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHOCLOCINNAMOX; MORPHINE; MU OPIATE RECEPTOR; OPIATE AGONIST; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RHESUS MONKEY;

ANIMALS; BUPRENORPHINE; CINNAMATES; DRUG ANTAGONISM; HEROIN; MACACA MULATTA; MORPHINE; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; NARCOTICS; RECEPTORS, OPIOID, MU; RESPIRATION; TIME FACTORS;

EID: 0034677963     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00039-X     Document Type: Article

References (15)

1. Briscoe R.J., Winger G., Lewis J.W., Woods J.H. Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys. Psychopharmacology. 148:2000;393-399.
2. Butelman E.R., France C.P., Woods J.H. Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J. Pharmacol. Exp. Ther. 264:1993;145-151.
3. Butelman E.R., Lewis J.W., Woods J.H. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys. J. Pharmacol. Exp. Ther. 279:1996;934-938.
4. Cowan A., Doxey J.C., Harry E.J.R. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60:1977;547-554.
5. Cowan A., Lewis J.W., MacFarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60:1977;537-545.
6. Dum J., Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 74:1981;627-633.
7. France C.P., Woods J.H. Respiratory effects of receptor-selective opioids in rhesus monkeys. Quirion R., Jhamandas K., Gianoulakis C. The International Narcotic Research Conference (INRC) '89. 1990;295-298 A.R. Liss, New York, NY.
8. Howell L.L., Bergman J., Morse W.H. Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;364-372.
9. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interactions. 2nd edn. 1993;Raven Press, NY.
10. Liguori A., Morse W.H., Bergman J. Respiratory effects of opioid full and partial agonists in rhesus monkeys. J. Pharmacol. Exp. Ther. 227:1996;462-472.
11. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculations with Computer Programs. 1987;Springer-Verlag, New York.
12. Walker E.A., Zernig G., Woods J.H. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J. Pharmacol. Exp. Ther. 273:1995;1345-1352.
13. Winger G., Skjoldager P., Woods J.H. Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261:1992;311-317.
14. Woods J.H., France C.P., Winger G.D. Behavioral pharmacology of buprenorphine: issues relevant to its potential in treating drug abuse. Natl. Inst. Drug Abuse Res. Monogr. Ser. 121:1992;12-27.
15. Woods J.H., Lewis J.W., Winger G., Butelman E., Broadbear J., Zernig G. Methoclocinnamox: a μ partial agonist with pharmacotherapeutic potential for heroin abuse. Natl. Inst. Drug Abuse Res. Monogr. Ser. 147:1995;195-219.